IMMUNOASSAY PLATFORM - Accelerating Drug Development & Clinical Validation With Single Molecule Counting
Steven Suchyta, PhD, discusses how Ultrasensitive Single Molecule Counting technology provides an indispensable tool in the researcher’s arsenal to help move novel biology forward, fueling the discovery and development of new therapeutics.
CRO MARKET - CRO Sector: Sales & Margins Remain Healthy
Adam Dion, MSc, indicates declining R&D productivity and increased development costs have negatively impacted biopharmaceutical companies, and the need for them to maximize productivity and lower costs in their commercial operations will cause them to look to CRO partners as they enter into outsourcing arrangements.
NANOSCALE COMPLEXES - A Novel Nanotechnology-Based Platform to Optimize Combination Cancer Therapies: Rational Development & Improved Delivery Using CombiPlex®
Barry D. Liboiron, PhD; Arthur C. Louie, MD; et al describe how CombiPlex addresses the challenges facing the traditional development path of many contemporary drug combinations and provide clinical proof-of-principle evidence that this approach can yield marked improvements in efficacy and patient outcomes.
EXTERNAL DELIVERY - The New Marketing Paradigm
We are 60 days past the half-way mark for calendar 2015. For those on a calendar year fiscal basis, this means their business year is…
EXECUTIVE INTERVIEW - Enable Injections: Revolutionizing Treatment With a New Class of Devices
Michael Hooven, CEO of Enable Injections, discusses his vision for the company and how it intends to create marketleading biologics delivery devices that meet the most pressing needs of pharmaceutical companies while enabling easy patient self-administration for significant cost-savings.
Capsugel to Acquire Xcelience & Powdersize
Capsugel to Acquire Xcelience & Powdersize Xcelience provides the company with specialized clinical trial manufacturing and supply capabilities for a broad range of solid…
SINGLE-USE MARKET - Rise of Single-Use Technologies & Systems in Biopharmaceuticals
Kevin James and Shalini S. Dewan of BCC Research believe eliminating the risk of contamination is the greatest challenge faced by manufacturers of biopharmaceuticals, and currently, this requires high-level monitoring of critical manufacturing processes. Single-use technology aids biopharmaceutical manufacturers in overcoming this challenge by reducing or eliminating the need for sterilization between batches, thereby improving operational efficiency.
CELL CULTURE MARKET - 3D Cell Cultures: Next Generation & New Challenges
Kevin James and Robert G. Hunter of BCC Research say significant growth within the biopharmaceuticals industry is spurring unprecedented innovation in and demand for cell culture products for the purposes of drug discovery and safety testing. While 2D cell cultures have been in laboratory use since the 1950s, the market for 3D cultures has witnessed spectacular growth throughout the past decade.
DIAGNOSTIC TESTING - Diabetes Diagnostic Testing: A Move From Invasive to Non-Invasive Testing
Divyaa Ravishankar, Frost & Sullivan Analyst, focuses on the innovations around self-monitoring glucose meters and continuous glucose monitoring devices, providing in-depth competitive intelligence on some of the technologies and non-invasive techniques.
DRUG DEVICE MARKET - Joining Forces: Global Markets for Drug-Device Combinations
Kevin James and Kevin Gainer of BCC Research indicate the development of the market for combination products is closely related to the drug delivery systems sector, which represents a vast area of research and the demand for sophisticated drug delivery devices behind many novel product developments.
COLORECTAL CANCER MARKET - Targeted & Immune System-Based Therapeutics Emerge as Prominent Treatment Modalities
Barbara Gilmore, Frost & Sullivan Analyst, reports that a vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and significant commercial potential are attracting drug developers to the market.
STEM CELL MARKET - Stem Cell Therapy to Redefine Regenerative Medicine
Jane C. Andrews, PhD, Frost & Sullivan Analyst, says faced with increasing challenges, such as costly treatments and treatments that are palliative rather than symptomatic, the global healthcare industry today is gradually transforming itself. With few existing therapies capable of curing or significantly changing the course of a disease, healthcare providers are starting to look toward regenerative medicine as a viable alternative.
ALBUMIN MARKET - Global Human Albumin Market: Extra Revenues to Come Through Non-Therapeutic Applications
Aish Vivekanandan, Frost & Sullivan Analyst, reports that human albumin is widely considered as a plasma replacement or expander for therapeutic purposes. However, for over a decade, the healthcare industry has been exploring the use of human albumin as a non-therapeutic substance/excipient for commercial settings.
MICRONEEDLE TECHNOLOGY - The New Potential of Microneedles for Biologics & Small Molecules
Lisa A. Dick, PhD, describes how microneedle technology is being applied in two new transdermal systems using solid and hollow microneedles, which have the ability to deliver small molecules as well as biologics, opening up the potential for self-administration of a broad array of APIs
LOC-BASED DEVICES - Lab on Chip – How Far Are We Along the Road?
Divyaa Ravishankar, MS, indicates LOC-based devices are an integration of multiple disciplines and the miniaturization of the major laboratory procedures. Recently, these devices are branching into additional aspects of healthcare, such as drug delivery, stem cell, environmental monitoring, and synthetic biology.
EXECUTIVE INTERVIEW - Unither Pharmaceuticals: Premeasured Dosage Forms to Improve Medication Adherence
Eric Goupil, CEO Unither Pharmaceuticals, speaks frankly about medication adherence, Unither’s technology, and some of the challenges that they face today.
ADVANCED DELIVERY DEVICES - Implantable Drug-Eluting Devices: A Novel Approach to Patient Care
Samuel D. Trohman, MBA, Joey L. Glassco, Elena Draganoiu, PhD, and Carey Boyum present developmental and commercial examples of non-biodegradable drug-eluting devices, along with the versatile properties of thermoplastic polyurethanes for the development of effective drug delivery systems.
FORMULATION DEVELOPMENT TECHNOLOGY - A Novel Drug Delivery System That Offers Zero-Order/Near Zero-Order Release Profile of Low-Dosage Strength Tablets Containing Highly Soluble Actives
Thomas B. Gold, PhD, was awarded a US patent; the intellectual property centers on formulation development technology that allows for the steady, continuous release of API over a particular duration of time to mitigate variations or spikes in therapeutic benefit.
SYRINGE SYSTEM - The Credence Companion Syringe System Delivers on Safety & Usability Using Human Factors Studies
John A. Merhige, MEM, and Lisa Caparra, RN, explain how development of the Companion product line has been driven by these two constituents, the innovation driven by the end-users’ needs and the avoidance of change driven by needs of the drug manufacturer.
EXECUTIVE INTERVIEW - ALTHEA: Giving Biopharmaceutical Companies the Power To Make
David Enloe, Althea’s President and CEO, discusses his company’s business strategy, why companies choose Althea, trends in the CMO industry, and how the company is growing since the acquisition of Ajinomoto.
